2-[3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl]-3(2H)-pyridazinone | 110696-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-[3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl]-3(2H)-pyridazinone
• 英文别名: 3(2H)-Pyridazinone, 2-[3-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]propyl]-；2-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]pyridazin-3-one
• CAS: 110696-42-9
• 化学式: C₁₆H₁₉N₃O₃
• 分子量: 301.345
• InChiKey: FJNRJBQUOQLUNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl]-3(2H)-pyridazinone 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 40.0 ℃ 、2.0 MPa 条件下， 反应 3.0h， 以55%的产率得到2-[3-(2,3-Dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]-4,5-dihydropyridazin-3-one
  参考文献：
  名称：

  Synthesis, antihypertensive and α-adrenoceptor activity of novel 2-aminoalkyl-3(2H)-pyridazinones

  摘要：

  A number of 2-phenoxyalkylaminoalkyl- and 2-[1,4]benzodioxanylmethylaminoalkyl-3(2H)-pyridazinones were synthesized and tested for hypotensive and antihypertensive activity as well as for alpha-1- and alpha-2-adrenoceptor binding affinities. Some derivatives, eg 5.5, 5.9, 5.12, 6.4 and 6.10, showed strong hypotensive/antihypertensive effect and high affinity for alpha-2- and alpha-1-adrenoceptors. Compound 5.5 was selected for clinical study. In its mode of action a potassium channel opening activity may also be involved.

  DOI：

  10.1016/0223-5234(92)90098-l
• 作为产物：
  描述：

  N-benzyl-N-chloropropyl-2-(1,4)-benzodioxanylmethylamine 在 palladium on activated charcoal 盐酸 、 四丁基溴化铵 、 氢气 作用下， 以 乙醇 、 苯 为溶剂， 反应 3.0h， 生成 2-[3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl]-3(2H)-pyridazinone
  参考文献：
  名称：

  Synthesis, antihypertensive and α-adrenoceptor activity of novel 2-aminoalkyl-3(2H)-pyridazinones

  摘要：

  A number of 2-phenoxyalkylaminoalkyl- and 2-[1,4]benzodioxanylmethylaminoalkyl-3(2H)-pyridazinones were synthesized and tested for hypotensive and antihypertensive activity as well as for alpha-1- and alpha-2-adrenoceptor binding affinities. Some derivatives, eg 5.5, 5.9, 5.12, 6.4 and 6.10, showed strong hypotensive/antihypertensive effect and high affinity for alpha-2- and alpha-1-adrenoceptors. Compound 5.5 was selected for clinical study. In its mode of action a potassium channel opening activity may also be involved.

  DOI：

  10.1016/0223-5234(92)90098-l

文献信息

• [EN] 3(2H)-PYRIDAZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS<br/>[FR] DERIVES DE 3(2H)-PYRIDAZINONE ET COMPOSITIONS PHARMACEUTIQUES A BASE DE CES COMPOSES
  申请人：GYÓGYSZERKUTATÓ INTÉZET KFT

  公开号：WO1996038441A1

  公开（公告）日：1996-12-05

  (EN) The invention relates to R-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (1), and to S-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (2), and to acid-addition salts thereof as well as pharmaceutical compositions containing these compounds. Furthermore, the invention relates to a process for the preparation of the above compounds. The new starting compounds of formulae (4) and (5) are also involved in the scope of the invention. The compounds according to the invention possess $g(a)1- and $g(a)2-adrenoceptor antagonistic effects and urogenital selectivity. Thus, they are useful for the treatment of the benign prostate hyperplasia.(FR) L'invention se rapporte aux composés R-2-[3-([1,4]benzodioxan-2-ylméthylamino)-1-propyl]-3(2H)-pyridazinone de formule (1), et S-2-[3-([1,4]benzodioxan-2-ylméthylamino)-1-propyl]-3(2H)-pyridazinone de formule (2), ainsi qu'aux sels d'addition d'acide desdits composés et aux compositions pharmaceutiques à base de ces composés. On décrit aussi un procédé relatif à l'élaboration de ces composés. Par ailleurs, le champ de l'invention s'étend aux nouveaux composés de départ correspondant aux formules (4) et (5). Les composés considérés sont des antagonistes du récepteur $g(a)1- et $g(a)2-adrénergique et ont un potentiel de sélectivité uro-génitale. Ils sont donc utiles dans le traitement de l'adénome prostatique.

  本发明涉及式（1）的R-2-[3-（[1,4]苯并二氧杂环-2-基甲基氨基）-1-丙基]-3（2H）-吡啶酮，式（2）的S-2-[3-（[1,4]苯并二氧杂环-2-基甲基氨基）-1-丙基]-3（2H）-吡啶酮，以及它们的酸盐加合物和含有这些化合物的药物组合物。此外，本发明还涉及制备上述化合物的方法。式（4）和（5）的新起始化合物也包括在本发明的范围内。根据本发明，这些化合物具有$g(a)1-和$g(a)2-肾上腺素受体拮抗作用和泌尿生殖器选择性。因此，它们可用于治疗良性前列腺增生症。
• Agents and crystals for improving excretory potency of urinary bladder
  申请人：Ishihara Yuji

  公开号：US20090264467A1

  公开（公告）日：2009-10-22

  Agents for improving potency of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As an example, crystals of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.

  提高膀胱功能的药物，包括一种非卡巴酯类胺化合物，具有乙酰胆碱酯酶抑制作用。具体而言，提供了一种三环、紧缩、杂环衍生物的晶体，其具有优异的抑制乙酰胆碱酯酶的作用和改善膀胱排泄功能的作用。例如，披露了8-[3-[1-[(3-氟苯基)-甲基]-4-哌啶基]-1-氧代丙基]-1,2,5,6-四氢-4H-吡咯并[3,2,1-ij]喹啉-4-酮或其盐以及含有它们的制药组合物。
• 3(2H)-pyridazinone derivatives, a process and intermediates for preparing them and medicaments containing them and/or other 3(2H)-pyridazinone derivatives
  申请人：RICHTER GEDEON VEGYESZETI GYAR R.T.

  公开号：EP0220735A2

  公开（公告）日：1987-05-06

  The subject-matter of the invention are 3(2H)-Pyridazinone derivatives of the general formula wherein R stands for an ethyl or propyl group substituted by a terminal halogen atom or hydroxyl group or a terminal group of the formula in which latter R₁ represents a hydrogen atom or an optionally substituted benzyl group and R₂ represents a hydrogen atom or an optionally substituted benzo[1,4]dioxan-2-yl-methyl or benzo[1,4]dioxan-2-yl-ethyl group or a group of the formula in which latter n is 2 or 3 and R₃ stands for an optionally substituted phenoxy or phenylthio group and X stands for a hydrogen or halogen atom or an optionally substituted saturated or unsaturated 5- or 6-membered heterocyclic group. Furthermore the subject-matter of the invention are a process and intermediates for preparing these compounds and medicaments containing them and/or other 3(2H)-pyridazinone derivatives. The compounds according to the invention inhibit the adrenergic alpha₁ receptors, have a calcium­-antagonistic effect and exert blood pressure lowering action.

  本发明的主题是通式为 3(2H)-哒嗪酮的衍生物 其中 R 代表被末端卤原子或羟基或通式末端基团取代的乙基或丙基 其中 R₁ 代表氢原子或任选取代的苄基，以及 R₂ 代表氢原子或任选取代的苯并[1,4]二噁烷-2-基-甲基或苯并[1,4]二噁烷-2-基-乙基或式 其中 n 为 2 或 3，且 R₃ 代表任选取代的苯氧基或苯硫基，以及 X 代表氢原子或卤素原子或任选取代的饱和或不饱和 5 或 6 元杂环基团。 此外，本发明的主题是制备这些化合物和含有这些化合物和/或其他 3(2H)-哒嗪酮衍生物的药物的工艺和中间体。 本发明的化合物可抑制肾上腺素能α₁受体，具有钙拮抗作用和降血压作用。
• Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1891954A2

  公开（公告）日：2008-02-27

  The invention relates to a compound of the formula or a salt thereof for improving excretory potency of the urinary bladder, such as for treating or preventing dysuria and for treating or preventing difficulty of urination. The invention further relates to a pharmaceutical composition comprising said compound.

  本发明涉及一种式如下的化合物 或其盐，用于改善膀胱的排泄能力，如治疗或预防排尿困难以及治疗或预防排尿困难。本发明还涉及一种包含上述化合物的药物组合物。
• KRASZICINER, ENDRE;MAKK, NANDOR;CZAKO, KLARA;KOSARY, JUDIT;RABLOCZKY, GYO+
  作者：KRASZICINER, ENDRE、MAKK, NANDOR、CZAKO, KLARA、KOSARY, JUDIT、RABLOCZKY, GYO+

  DOI：——

  日期：——